scholarly journals Impaired neurogenesis, neuronal loss, and brain functional deficits in the APPxPS1-Ki mouse model of Alzheimer's disease

2011 ◽  
Vol 32 (3) ◽  
pp. 407-418 ◽  
Author(s):  
A. Faure ◽  
L. Verret ◽  
B. Bozon ◽  
N. El Tannir El Tayara ◽  
M. Ly ◽  
...  
2006 ◽  
Vol 2 ◽  
pp. S106-S106
Author(s):  
Henning Breyhan ◽  
Stefanie Schäfer ◽  
Oliver Wirths ◽  
Martina Muckenthaler ◽  
Gerd Multhaup ◽  
...  

PLoS ONE ◽  
2013 ◽  
Vol 8 (4) ◽  
pp. e59586 ◽  
Author(s):  
Amanda L. Wright ◽  
Raphael Zinn ◽  
Barbara Hohensinn ◽  
Lyndsey M. Konen ◽  
Sarah B. Beynon ◽  
...  

2019 ◽  
Vol 20 (16) ◽  
pp. 3992 ◽  
Author(s):  
Sujin Kim ◽  
Yunkwon Nam ◽  
Yu-on Jeong ◽  
Hyun Ha Park ◽  
Seong-kyung Lee ◽  
...  

It is widely known that the degeneration of neural circuits is prominent in the brains of Alzheimer’s disease (AD) patients. The reciprocal connectivity of the medial septum (MS) and hippocampus, which constitutes the septo-hippocampo-septal (SHS) loop, is known to be associated with learning and memory. Despite the importance of the reciprocal projections between the MS and hippocampus in AD, the alteration of bidirectional connectivity between two structures has not yet been investigated at the mesoscale level. In this study, we adopted AD animal model, five familial AD mutations (5XFAD) mice, and anterograde and retrograde tracers, BDA and DiI, respectively, to visualize the pathology-related changes in topographical connectivity of the SHS loop in the 5XFAD brain. By comparing 4.5-month-old and 14-month-old 5XFAD mice, we successfully identified key circuit components of the SHS loop altered in 5XFAD brains. Remarkably, the SHS loop began to degenerate in 4.5-month-old 5XFAD mice before the onset of neuronal loss. The impairment of connectivity between the MS and hippocampus was accelerated in 14-month-old 5XFAD mice. These results demonstrate, for the first time, topographical evidence for the degradation of the interconnection between the MS and hippocampus at the mesoscale level in a mouse model of AD. Our results provide structural and functional insights into the interconnectivity of the MS and hippocampus, which will inform the use and development of various therapeutic approaches that target neural circuits for the treatment of AD.


2008 ◽  
Vol 4 ◽  
pp. T234-T234
Author(s):  
Michael Hierzer ◽  
Manuela Prokesch ◽  
Maria Posch ◽  
Stephan Duller ◽  
Birgit Hutter-Paier ◽  
...  

2015 ◽  
Vol 2015 ◽  
pp. 1-11 ◽  
Author(s):  
Carla Cirillo ◽  
Elena Capoccia ◽  
Teresa Iuvone ◽  
Rosario Cuomo ◽  
Giovanni Sarnelli ◽  
...  

Among the different signaling molecules released during reactive gliosis occurring in Alzheimer’s disease (AD), the astrocyte-derived S100B protein plays a key role in neuroinflammation, one of the hallmarks of the disease. The use of pharmacological tools targeting S100B may be crucial to embank its effects and some of the pathological features of AD. The antiprotozoal drug pentamidine is a good candidate since it directly blocks S100B activity by inhibiting its interaction with the tumor suppressor p53. We used a mouse model of amyloid beta- (Aβ-) induced AD, which is characterized by reactive gliosis and neuroinflammation in the brain, and we evaluated the effect of pentamidine on the main S100B-mediated events. Pentamidine caused the reduction of glial fibrillary acidic protein, S100B, and RAGE protein expression, which are signs of reactive gliosis, and induced p53 expression in astrocytes. Pentamidine also reduced the expression of proinflammatory mediators and markers, thus reducing neuroinflammation in AD brain. In parallel, we observed a significant neuroprotection exerted by pentamidine on CA1 pyramidal neurons. We demonstrated that pentamidine inhibits Aβ-induced gliosis and neuroinflammation in an animal model of AD, thus playing a role in slowing down the course of the disease.


Sign in / Sign up

Export Citation Format

Share Document